Patent 12290598
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Active provider: Google · gemini-2.5-pro
PTAB activity (1)
AIA trial proceedings — IPR, PGR, CBM — filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced directly from the PTAB Trial API.
- PGR2025-00086PGRfiled Sep 19, 2025vs. Dr. Falk Pharma GmbHTrial Instituted
Cached for 24 hours. Status strings are sourced verbatim from the PTAB API; the colored badge is our heuristic classification.
Cases on file (1)
Group view →Specific litigation cases in our database that name US patent 12290598. The free-form analysis below may also discuss cases beyond this list.
- Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P.filed Sep 19, 2025PGR2025-00086United States Patent and Trademark Office, Patent Trial and Appeal Board (PTAB)Pending
Defendants: Ellodi Pharmaceuticals, L.P.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Post-Grant Review Initiated for U.S. Patent No. 12,290,598
As of April 26, 2026, one litigation proceeding has been identified involving U.S. Patent No. 12,290,598, titled "Orally administered corticosteroid compositions." A Post-Grant Review (PGR) was filed with the Patent Trial and Appeal Board (PTAB).
Details of the case are as follows:
Case: PGR2025-00086
- Petitioner: Dr. Falk Pharma GmbH
- Patent Owner/Defendant: Ellodi Pharmaceuticals, L.P.
- Jurisdiction: United States Patent and Trademark Office, Patent Trial and Appeal Board (PTAB)
- Filing Date: September 19, 2025
- Status: Pending
The petitioner, Dr. Falk Pharma GmbH, is challenging the validity of claims 1-34 of the '598 patent. The grounds for the challenge include lack of written description and anticipation by a prior patent.
No other litigation in U.S. district courts or the Court of Appeals for the Federal Circuit involving this patent has been identified at this time.
Generated 5/13/2026, 12:49:14 PM